BRIEF-TG Therapeutics Announces Publication Of Results From The UNITY-NHL Phase 2b Trial
BRIEF-TG Therapeutics Announces Publication Of Results From The UNITY-NHL Phase 2b Trial
Brief-TG治療公司宣佈公佈Unity-NHL 2b期試驗的結果
March 9 (Reuters) - TG Therapeutics Inc :
* TG THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM THE UNITY-NHL PHASE 2B TRIAL EVALUATING UMBRALISIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* TG THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM THE UNITY-NHL PHASE 2B TRIAL EVALUATING UMBRALISIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 9 (Reuters) - TG Therapeutics Inc :
* TG THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM THE UNITY-NHL PHASE 2B TRIAL EVALUATING UMBRALISIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月9日電-TG治療公司:*TG治療公司宣佈在臨牀腫瘤學雜誌上發表評估復發或難治性惰性非霍奇金淋巴瘤患者的UMBRALISIB單一療法的Unity-NHL 2B期試驗的結果Eikon的源文本:進一步的公司報道:(Reurs.Briefs@thomsonreurs.com;)
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!